13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001940272
Total reported value
$2.2B
$2.2B
247 檔
8.1%
The Q1 2024 SEC filing reveals that ADAR1 Capital Management, LLC held a total portfolio value of $2.2B, covering 247 public equity positions.
During Q1 2024, ADAR1 Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
Showing top 200 holdings (of 247 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 14.43% | — | +78.81% | |
| 2 | BOXX | Alpha Architect 1-3 Mnth Box | ETF-Other | 7.68% | -0.50% | — | |
| 3 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 6.68% | -0.25% | +121.47% | |
| 4 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 6.17% | +2.36% | — | |
| 5 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 5.16% | -0.78% | +291.15% | |
| 6 | CYTK | Cytokinetics Inc | Stock-Healthcare | 5.12% | -0.66% | +90.78% | |
| 7 | KROS | Keros Therapeutics Inc | Stock-Other | 5.08% | +0.06% | -50.86% | |
| 8 | RPRX | Royalty Pharma plc | Stock-Healthcare | 4.97% | +0.02% | -45.43% | |
| 9 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.87% | +0.19% | +197.62% | |
| 10 | MACKEUR | Merrimack Pharmaceuticals In | Stock-Other | 3.02% | — | +64.24% | |
| 11 | ASND | Ascendis Pharma A/S | Stock-Other | 1.67% | -0.34% | EXIT | |
| 12 | ABUS | Arbutus Biopharma CORP | Stock-Other | 1.21% | -0.55% | -43.12% | |
| 13 | ✓ | Stock-Other | 1.15% | — | +7786.53% | ||
| 14 | ONC | Beone Medicines Ltd-adr | Stock-Other | 1.12% | -0.05% | +1453.50% | |
| 15 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 1.01% | — | — | |
| 16 | ALKS | Alkermes plc | Stock-Healthcare | 0.96% | -0.10% | EXIT | |
| 17 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.95% | — | — | |
| 18 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.95% | +0.26% | +300.71% | |
| 19 | 0C3 | Endeavor Group Hold-class A | Stock-Other | 0.91% | — | +6110.00% | |
| 20 | ACHV | Achieve Life Sciences Inc | Stock-Other | 0.90% | +0.01% | — | |
| 21 | ✓ | Fusion Pharmaceuticals Inc | Stock-Other | 0.86% | — | — | |
| 22 | ABSI | Absci CORP | Stock-Other | 0.76% | — | — | |
| 23 | APLT | Applied Therapeutics Inc | Stock-Other | 0.75% | — | — | |
| 24 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.75% | +0.10% | — | |
| 25 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.73% | +0.20% | -46.69% | |
| 26 | QTTB | Q32 Bio Inc | Stock-Other | 0.73% | -0.01% | EXIT | |
| 27 | CERE1EUR | Cerevel Therapeutics Holding | Stock-Other | 0.71% | — | -53.72% | |
| 28 | BIL | Ss Spdr Bb 1-3m T-bill ETF | ETF-Gov Bonds | 0.68% | -0.16% | +1.56% | |
| 29 | PFE | Pfizer Inc | Stock-Healthcare | 0.67% | +0.15% | +76.06% | |
| 30 | VUSB | Vanguard Ultra Short Bond Et | ETF-Other | 0.62% | — | +9.96% | |
| 31 | JPST | Jpmorgan Ultra-short Income | ETF-Other | 0.62% | — | +10.20% | |
| 32 | SHV | Ishares 0-1 Year Treasury Bo | ETF-Gov Bonds | 0.61% | — | — | |
| 33 | SLDB | Solid Biosciences Inc | Stock-Other | 0.61% | — | +20220.40% | |
| 34 | USFR | Wisdomtree Floating Rate Tre | ETF-Other | 0.60% | -0.01% | -5.36% | |
| 35 | CLRBUSD | Cellectar Biosciences Inc | Stock-Other | 0.58% | — | -53.37% | |
| 36 | OABI | Omniab Inc | Stock-Other | 0.56% | +0.04% | -5.58% | |
| 37 | GH | Guardant Health Inc | Stock-Healthcare | 0.55% | -0.05% | EXIT | |
| 38 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.53% | -0.09% | EXIT | |
| 39 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.50% | +0.08% | — | |
| 40 | IBIO | Ibio Inc | Stock-Other | 0.50% | -0.02% | — | |
| 41 | CTVA | Corteva Inc | Stock-Materials | 0.49% | — | -35.52% | |
| 42 | ✓ | Beyond Air Inc | Stock-Other | 0.48% | — | — | |
| 43 | IMVT | Immunovant Inc | Stock-Other | 0.45% | +0.19% | -54.70% | |
| 44 | LGND | Ligand Pharmaceuticals | Stock-Healthcare | 0.44% | — | — | |
| 45 | ULST | Ss Ultra Short Tm Bond ETF | ETF-Other | 0.44% | — | -22.17% | |
| 46 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.43% | +0.15% | +668.63% | |
| 47 | SDGR | Schrodinger Inc | Stock-Other | 0.39% | -0.07% | EXIT | |
| 48 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.36% | — | -13.19% | |
| 49 | QURE | uniQure N.V. | Stock-Other | 0.35% | +0.51% | — | |
| 50 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.34% | -0.17% | EXIT |
According to official SEC Form 13F filings, ADAR1 Capital Management, LLC reported a total U.S. public equity portfolio value of $2.2B across 247 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ALNY, BOXX, ROIV) accounted for 8.1% of total reported equity market value during Q1 2024.
During Q1 2024, ADAR1 Capital Management, LLC's top holdings by market value included ALNY (14.4%)、BOXX (7.7%)、ROIV (6.7%). The largest single position, ALNY, represented 14.4% of total portfolio value.
In Q1 2024, ADAR1 Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.